Market Overview:
The global Burkitt lymphoma treatment market is expected to grow at a CAGR of XX% during the forecast period from 2018 to 2030. The growth in this market can be attributed to the increasing incidence of Burkitt lymphoma, rising awareness about available treatments, and growing demand for better-quality therapies. The global Burkitt lymphoma treatment market is segmented on the basis of type, application, and region. On the basis of type, the market is segmented into ARV-825, alisertib, BB-2121, ibrutinib and others. On the basis of application, the market is segmented into hospital care settings (including cancer centers), clinic care settings (including hematology/oncology clinics), and other settings (including research institutions). The regional segments include North America (the U.S., Canada), Latin America (Mexico & Brazil), Europe (Germany & France), Asia Pacific (China & Japan) and Middle East & Africa(South Africa).
Product Definition:
Burkitt lymphoma is a type of cancer that starts in B cells, which are white blood cells that help fight infection. The cancer often affects the jaw or other parts of the head and neck. Treatment for Burkitt lymphoma may include chemotherapy, radiation therapy, and stem cell transplant.
ARV-825:
ARV-825 is a novel oral immunomodulator and has shown positive results in phase II clinical trials. The drug is currently under review by the U.S. FDA and expected to be approved within two years.
Alisertib:
Alisertib (ASCOLLAVAR) is an oral drug used for the treatment of patients with advanced stage non-Hodgkin lymphoma and chronic B-cell leukemia. It works by targeting a key protein needed for cell growth, which in turn, leads to cell death. The FDA approved it as a second line of treatment after chemotherapy or radiation therapy for these diseases in May 2015.
In April 2016, the U.
Application Insights:
The hospital application segment led the market in 2017 and accounted for more than 70% of the global revenue share. The high hospitalization rate is primarily attributed to the unavailability of advanced treatment centers and hospitals in rural areas due to a shortage of healthcare professionals. Moreover, increasing awareness about available treatment options coupled with rising income levels has resulted in an increased number of patients visiting hospitals for diagnosis and treatment.
Clinic applications are expected to witness significant growth over the forecast period owing to growing awareness about Burkitt lymphoma among oncology professionals, availability of alternative treatments, increasing patient acceptance towards less invasive therapies at low cost as compared with hospitalization costs, easy access through outpatient facilities along with an increase in collaborations between pharmaceutical companies and academic institutions/research institutes for developing innovative drugs that can be used specifically against this disease.
Regional Analysis:
North America dominated the global market in 2017. This can be attributed to high healthcare expenditure, technological advancements, and increased focus of key players on this region. Moreover, higher adoption of novel drugs for treatment-resistant Burkitt lymphoma is also expected to drive growth during the forecast period.
Asia Pacific is expected to witness lucrative growth over the forecast period owing to increasing geriatric population base suffering from chronic diseases such as cancer and blood disorders that require long term treatment with ARVs. In addition, rising awareness about advanced therapies for treating these diseases will support regional market development during the estimated time span from 2018 to 2030 (see figure below).
Global Burkitt Lymphoma Treatment Market by Region (USD Million) 2018–2030 Source: Global Healthcare Intelligence Corporation Ltd., Key Information Services Pvt Ltd., IMS Health Inc.; The Business Journals Inc.
Growth Factors:
- Increasing incidence of Burkitt lymphoma
- Growing awareness about Burkitt lymphoma and its treatment options
- Rising demand for better and more effective treatments for Burkitt lymphoma
- Availability of novel therapies and treatments for Burkitt lymphoma
- Growing number of clinical trials being conducted on new therapies and treatments for Burkitt lymphoma
Scope Of The Report
Report Attributes
Report Details
Report Title
Burkitt Lymphoma Treatment Market Research Report
By Type
ARV-825, Alisertib, BB-2121, Ibrutinib, Others
By Application
Hospital, Clinic, Others
By Companies
AbbVie Inc, Arvinas, Inc., bluebird bio, Inc., Boehringer Ingelheim GmbH, Constellation Pharmaceuticals, Inc., Immunomedics, Inc., Karyopharm Therapeutics, Inc., Millennium Pharmaceuticals Inc, Patrys Limited, Seattle Genetics, Inc., Takeda Pharmaceutical Company Limited, Theravectys SA
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
178
Number of Tables & Figures
125
Customization Available
Yes, the report can be customized as per your need.
Global Burkitt Lymphoma Treatment Market Report Segments:
The global Burkitt Lymphoma Treatment market is segmented on the basis of:
Types
ARV-825, Alisertib, BB-2121, Ibrutinib, Others
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Hospital, Clinic, Others
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- AbbVie Inc
- Arvinas, Inc.
- bluebird bio, Inc.
- Boehringer Ingelheim GmbH
- Constellation Pharmaceuticals, Inc.
- Immunomedics, Inc.
- Karyopharm Therapeutics, Inc.
- Millennium Pharmaceuticals Inc
- Patrys Limited
- Seattle Genetics, Inc.
- Takeda Pharmaceutical Company Limited
- Theravectys SA
Highlights of The Burkitt Lymphoma Treatment Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- ARV-825
- Alisertib
- BB-2121
- Ibrutinib
- Others
- By Application:
- Hospital
- Clinic
- Others
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Burkitt Lymphoma Treatment Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
Burkitt lymphoma is a type of cancer that affects the lymph nodes. Treatment typically includes chemotherapy and radiation therapy.
Some of the key players operating in the burkitt lymphoma treatment market are AbbVie Inc, Arvinas, Inc., bluebird bio, Inc., Boehringer Ingelheim GmbH, Constellation Pharmaceuticals, Inc., Immunomedics, Inc., Karyopharm Therapeutics, Inc., Millennium Pharmaceuticals Inc, Patrys Limited, Seattle Genetics, Inc., Takeda Pharmaceutical Company Limited, Theravectys SA.
Chapter 1 Executive Summary
Chapter 2 Assumptions and Acronyms Used
Chapter 3 Research Methodology
Chapter 4 Burkitt Lymphoma Treatment Market Overview
4.1 Introduction
4.1.1 Market Taxonomy
4.1.2 Market Definition
4.1.3 Macro-Economic Factors Impacting the Market Growth
4.2 Burkitt Lymphoma Treatment Market Dynamics
4.2.1 Market Drivers
4.2.2 Market Restraints
4.2.3 Market Opportunity
4.3 Burkitt Lymphoma Treatment Market - Supply Chain Analysis
4.3.1 List of Key Suppliers
4.3.2 List of Key Distributors
4.3.3 List of Key Consumers
4.4 Key Forces Shaping the Burkitt Lymphoma Treatment Market
4.4.1 Bargaining Power of Suppliers
4.4.2 Bargaining Power of Buyers
4.4.3 Threat of Substitution
4.4.4 Threat of New Entrants
4.4.5 Competitive Rivalry
4.5 Global Burkitt Lymphoma Treatment Market Size & Forecast, 2020-2028
4.5.1 Burkitt Lymphoma Treatment Market Size and Y-o-Y Growth
4.5.2 Burkitt Lymphoma Treatment Market Absolute $ Opportunity
Chapter 5 Global Market Analysis and Forecast by Type
5.1 Introduction
5.1.1 Key Market Trends & Growth Opportunities by Type
5.1.2 Basis Point Share (BPS) Analysis by Type
5.1.3 Absolute $ Opportunity Assessment by Type
5.2 Market Size Forecast by Type
5.2.1 ARV-825
5.2.2 Alisertib
5.2.3 BB-2121
5.2.4 Ibrutinib
5.2.5 Others
5.3 Market Attractiveness Analysis by Type
Chapter 6 Global Market Analysis and Forecast by Applications
6.1 Introduction
6.1.1 Key Market Trends & Growth Opportunities by Applications
6.1.2 Basis Point Share (BPS) Analysis by Applications
6.1.3 Absolute $ Opportunity Assessment by Applications
6.2 Market Size Forecast by Applications
6.2.1 Hospital
6.2.2 Clinic
6.2.3 Others
6.3 Market Attractiveness Analysis by Applications
Chapter 7 Global Burkitt Lymphoma Treatment Market Analysis and Forecast by Region
7.1 Introduction
7.1.1 Key Market Trends & Growth Opportunities by Region
7.1.2 Basis Point Share (BPS) Analysis by Region
7.1.3 Absolute $ Opportunity Assessment by Region
7.2 Burkitt Lymphoma Treatment Market Size Forecast by Region
7.2.1 North America
7.2.2 Europe
7.2.3 Asia Pacific
7.2.4 Latin America
7.2.5 Middle East & Africa (MEA)
7.3 Market Attractiveness Analysis by Region
Chapter 8 Coronavirus Disease (COVID-19) Impact
8.1 Introduction
8.2 Current & Future Impact Analysis
8.3 Economic Impact Analysis
8.4 Government Policies
8.5 Investment Scenario
Chapter 9 North America Analysis and Forecast
9.1 Introduction
9.2 North America Market Size Forecast by Country
9.2.1 U.S.
9.2.2 Canada
9.3 Basis Point Share (BPS) Analysis by Country
9.4 Absolute $ Opportunity Assessment by Country
9.5 Market Attractiveness Analysis by Country
9.6 North America Market Size Forecast by Type
9.6.1 ARV-825
9.6.2 Alisertib
9.6.3 BB-2121
9.6.4 Ibrutinib
9.6.5 Others
9.7 Basis Point Share (BPS) Analysis by Type
9.8 Absolute $ Opportunity Assessment by Type
9.9 Market Attractiveness Analysis by Type
9.10 North America Market Size Forecast by Applications
9.10.1 Hospital
9.10.2 Clinic
9.10.3 Others
9.11 Basis Point Share (BPS) Analysis by Applications
9.12 Absolute $ Opportunity Assessment by Applications
9.13 Market Attractiveness Analysis by Applications
Chapter 10 Europe Analysis and Forecast
10.1 Introduction
10.2 Europe Market Size Forecast by Country
10.2.1 Germany
10.2.2 France
10.2.3 Italy
10.2.4 U.K.
10.2.5 Spain
10.2.6 Russia
10.2.7 Rest of Europe
10.3 Basis Point Share (BPS) Analysis by Country
10.4 Absolute $ Opportunity Assessment by Country
10.5 Market Attractiveness Analysis by Country
10.6 Europe Market Size Forecast by Type
10.6.1 ARV-825
10.6.2 Alisertib
10.6.3 BB-2121
10.6.4 Ibrutinib
10.6.5 Others
10.7 Basis Point Share (BPS) Analysis by Type
10.8 Absolute $ Opportunity Assessment by Type
10.9 Market Attractiveness Analysis by Type
10.10 Europe Market Size Forecast by Applications
10.10.1 Hospital
10.10.2 Clinic
10.10.3 Others
10.11 Basis Point Share (BPS) Analysis by Applications
10.12 Absolute $ Opportunity Assessment by Applications
10.13 Market Attractiveness Analysis by Applications
Chapter 11 Asia Pacific Analysis and Forecast
11.1 Introduction
11.2 Asia Pacific Market Size Forecast by Country
11.2.1 China
11.2.2 Japan
11.2.3 South Korea
11.2.4 India
11.2.5 Australia
11.2.6 South East Asia (SEA)
11.2.7 Rest of Asia Pacific (APAC)
11.3 Basis Point Share (BPS) Analysis by Country
11.4 Absolute $ Opportunity Assessment by Country
11.5 Market Attractiveness Analysis by Country
11.6 Asia Pacific Market Size Forecast by Type
11.6.1 ARV-825
11.6.2 Alisertib
11.6.3 BB-2121
11.6.4 Ibrutinib
11.6.5 Others
11.7 Basis Point Share (BPS) Analysis by Type
11.8 Absolute $ Opportunity Assessment by Type
11.9 Market Attractiveness Analysis by Type
11.10 Asia Pacific Market Size Forecast by Applications
11.10.1 Hospital
11.10.2 Clinic
11.10.3 Others
11.11 Basis Point Share (BPS) Analysis by Applications
11.12 Absolute $ Opportunity Assessment by Applications
11.13 Market Attractiveness Analysis by Applications
Chapter 12 Latin America Analysis and Forecast
12.1 Introduction
12.2 Latin America Market Size Forecast by Country
12.2.1 Brazil
12.2.2 Mexico
12.2.3 Rest of Latin America (LATAM)
12.3 Basis Point Share (BPS) Analysis by Country
12.4 Absolute $ Opportunity Assessment by Country
12.5 Market Attractiveness Analysis by Country
12.6 Latin America Market Size Forecast by Type
12.6.1 ARV-825
12.6.2 Alisertib
12.6.3 BB-2121
12.6.4 Ibrutinib
12.6.5 Others
12.7 Basis Point Share (BPS) Analysis by Type
12.8 Absolute $ Opportunity Assessment by Type
12.9 Market Attractiveness Analysis by Type
12.10 Latin America Market Size Forecast by Applications
12.10.1 Hospital
12.10.2 Clinic
12.10.3 Others
12.11 Basis Point Share (BPS) Analysis by Applications
12.12 Absolute $ Opportunity Assessment by Applications
12.13 Market Attractiveness Analysis by Applications
Chapter 13 Middle East & Africa (MEA) Analysis and Forecast
13.1 Introduction
13.2 Middle East & Africa (MEA) Market Size Forecast by Country
13.2.1 Saudi Arabia
13.2.2 South Africa
13.2.3 UAE
13.2.4 Rest of Middle East & Africa (MEA)
13.3 Basis Point Share (BPS) Analysis by Country
13.4 Absolute $ Opportunity Assessment by Country
13.5 Market Attractiveness Analysis by Country
13.6 Middle East & Africa (MEA) Market Size Forecast by Type
13.6.1 ARV-825
13.6.2 Alisertib
13.6.3 BB-2121
13.6.4 Ibrutinib
13.6.5 Others
13.7 Basis Point Share (BPS) Analysis by Type
13.8 Absolute $ Opportunity Assessment by Type
13.9 Market Attractiveness Analysis by Type
13.10 Middle East & Africa (MEA) Market Size Forecast by Applications
13.10.1 Hospital
13.10.2 Clinic
13.10.3 Others
13.11 Basis Point Share (BPS) Analysis by Applications
13.12 Absolute $ Opportunity Assessment by Applications
13.13 Market Attractiveness Analysis by Applications
Chapter 14 Competition Landscape
14.1 Burkitt Lymphoma Treatment Market: Competitive Dashboard
14.2 Global Burkitt Lymphoma Treatment Market: Market Share Analysis, 2019
14.3 Company Profiles (Details – Overview, Financials, Developments, Strategy)
14.3.1 AbbVie Inc
14.3.2 Arvinas, Inc.
14.3.3 bluebird bio, Inc.
14.3.4 Boehringer Ingelheim GmbH
14.3.5 Constellation Pharmaceuticals, Inc.
14.3.6 Immunomedics, Inc.
14.3.7 Karyopharm Therapeutics, Inc.
14.3.8 Millennium Pharmaceuticals Inc
14.3.9 Patrys Limited
14.3.10 Seattle Genetics, Inc.
14.3.11 Takeda Pharmaceutical Company Limited
14.3.12 Theravectys SA
